Robert Olstein's PBH Position Overview
Robert Olstein (via Olstein Capital Management, L.P.) currently holds 21,000 shares of Prestige Consumer Healthcare Inc. (PBH) worth $1.31 M, representing 0.25% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 35 quarters.
Based on 13F filings, Robert Olstein has maintained a strategic position in PBH, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2018, adding 51,900 shares. Largest reduction occurred in Q2 2018, reducing 25,445 shares.
Analysis based on 13F filings available since 2013 Q2
Robert Olstein's Prestige Consumer Healthcare (PBH) Holding Value Over Time
Track share changes against reported price movement
Quarterly Prestige Consumer Healthcare (PBH) Trades by Robert Olstein
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2017 | +33,330 | New Buy | 33,330 | $55.57 |
| Q2 2017 | +14,080 | Add 42.24% | 47,410 | $52.82 |
| Q3 2017 | +12,340 | Add 26.03% | 59,750 | $50.09 |
| Q4 2017 | +48,100 | Add 80.50% | 107,850 | $44.41 |
| Q1 2018 | +51,900 | Add 48.12% | 159,750 | $33.72 |
| Q2 2018 | -25,445 | Reduce 15.93% | 134,305 | $38.38 |
| Q3 2018 | -23,000 | Reduce 17.13% | 111,305 | $37.89 |
| Q4 2018 | -13,505 | Reduce 12.13% | 97,800 | $30.88 |
| Q1 2019 | +15,200 | Add 15.54% | 113,000 | $29.91 |
| Q2 2019 | -14,000 | Reduce 12.39% | 99,000 | $31.68 |
| Q3 2019 | -22,000 | Reduce 22.22% | 77,000 | $34.69 |
| Q4 2019 | -13,000 | Reduce 16.88% | 64,000 | $40.50 |
| Q1 2020 | -19,000 | Reduce 29.69% | 45,000 | $36.69 |
| Q2 2020 | -8,000 | Reduce 17.78% | 37,000 | $37.57 |
| Q3 2020 | +4,000 | Add 10.81% | 41,000 | $36.41 |
| Q4 2020 | +43,000 | Add 104.88% | 84,000 | $34.87 |
| Q1 2021 | +24,000 | Add 28.57% | 108,000 | $44.08 |
| Q2 2021 | -2,000 | Reduce 1.85% | 106,000 | $52.10 |
| Q3 2021 | -20,000 | Reduce 18.87% | 86,000 | $56.10 |
| Q4 2021 | -13,000 | Reduce 15.12% | 73,000 | $60.64 |
| Q1 2022 | -5,000 | Reduce 6.85% | 68,000 | $52.94 |
| Q2 2022 | -7,000 | Reduce 10.29% | 61,000 | $58.80 |
| Q3 2022 | -6,000 | Reduce 9.84% | 55,000 | $49.84 |
| Q4 2022 | -7,335 | Reduce 13.34% | 47,665 | $62.60 |
| Q1 2023 | +1,335 | Add 2.80% | 49,000 | $62.63 |
| Q3 2023 | -6,000 | Reduce 12.24% | 43,000 | $57.19 |
| Q1 2024 | -4,000 | Reduce 9.30% | 39,000 | $72.56 |
| Q2 2024 | +10,000 | Add 25.64% | 49,000 | $68.86 |
| Q3 2024 | -14,000 | Reduce 28.57% | 35,000 | $72.11 |
| Q4 2024 | -9,000 | Reduce 25.71% | 26,000 | $78.08 |
| Q1 2025 | -11,000 | Reduce 42.31% | 15,000 | $86.00 |
| Q2 2025 | -3,000 | Reduce 20.00% | 12,000 | $79.83 |
| Q3 2025 | +9,000 | Add 75.00% | 21,000 | $62.38 |
Robert Olstein's Prestige Consumer Healthcare Investment FAQs
Robert Olstein first purchased Prestige Consumer Healthcare Inc. (PBH) in Q1 2017, acquiring 33,330 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Robert Olstein has held Prestige Consumer Healthcare Inc. (PBH) for 35 quarters since Q1 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Robert Olstein's largest addition to Prestige Consumer Healthcare Inc. (PBH) was in Q1 2018, adding 159,750 shares worth $5.39 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Robert Olstein's firm, Olstein Capital Management, L.P., owns 21,000 shares of Prestige Consumer Healthcare Inc. (PBH), valued at approximately $1.31 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Prestige Consumer Healthcare Inc. (PBH) represents approximately 0.25% of Robert Olstein's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Robert Olstein's peak holding in Prestige Consumer Healthcare Inc. (PBH) was 159,750 shares, as reported at the end of Q1 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.